Acer Therapeutics Overview

  • Status
  • Public
  • Employees
  • 23
Employees
  • Stock Symbol
  • ACER
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $2.52
  • (As of Tuesday Closing)

Acer Therapeutics General Information

Description

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

Contact Information

Website
www.acertx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • One Gateway Center
  • Suite 351, 300 Washington Street
  • Newton, MA 02458
  • United States
+1 (844) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Acer Therapeutics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.52 $2.52 $2.28 - $5.39 $36.1M 14.3M 230K -$1.34

Acer Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 25,027 26,029 24,360 156,081
Revenue 3,998 0 0 0
EBITDA (17,355) (22,828) (29,831) (21,666)
Net Income (16,906) (22,885) (29,418) (21,281)
Total Assets 39,984 14,614 21,466 50,663
Total Debt 0 364 590 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Acer Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Acer Therapeutics‘s full profile, request access.

Request a free trial

Acer Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Acer Therapeutics‘s full profile, request access.

Request a free trial

Acer Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development,
Pharmaceuticals
Newton, MA
23 As of 2021
0000
000000 - 000 0000

00000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000 000000000
San Diego, CA
00 As of 0000
00000
000000000 00000

00000000

iat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deseru
0000 000000000
New Haven, CT
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Acer Therapeutics Competitors (76)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA 00 00000 000000000 00000
00000000 Venture Capital-Backed New Haven, CT 00 00000 00000000 00000
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 0000000000 0 00000
00000 000000000000 Corporation NY 0 00.000 00000000 00.000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
You’re viewing 5 of 76 competitors. Get the full list »

Acer Therapeutics Executive Team (14)

Name Title Board Seat Contact Info
Chris Schelling Chief Executive Officer & Board Member
John Klopp Chief Technology Officer, Technology
Donald Joseph Secretary, Administration & Chief Legal Officer, Legal
Matthew Seibt Executive
Jim DeNike Executive Director, Investor Relations & Corporate Communications
You’re viewing 5 of 14 executive team members. Get the full list »

Acer Therapeutics Board Members (8)

Name Representing Role Since
Chris Schelling Acer Therapeutics Chief Executive Officer & Board Member 000 0000
Hubert Birner Ph.D Self Board Member 000 0000
John Dunn JD Acer Therapeutics Board Member 000 0000
Luc Marengère Ph.D TVM Capital Board Member 000 0000
Michelle Griffin Acer Therapeutics Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Acer Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acer Therapeutics Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 19-Sep-2017 000000000000000000 000 Biotechnology 00000 000000000
Anchor Therapeutics 20-Mar-2015 Merger/Acquisition Drug Discovery
To view Acer Therapeutics’s complete acquisitions history, request access »

Acer Therapeutics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 20-Mar-2015 000000000000000000 Completed
  • 0000 000000000000
To view Acer Therapeutics’s complete exits history, request access »